Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharma giant expects to have 24 to 28 programs in Phase III development by the end of 2009, representing a 50 percent to 70 percent increase, management says during an analyst day March 5. Pain and oncology are key disease areas Pfizer will focus on going forward. Investors, however, were unimpressed with the show
You may also be interested in...
Pfizer’s IGF-1 Inhibitor Leads Pack In Phase III For NSCLC
Pfizer's CP-751,871 for metastatic non-small cell lung cancer recently became the first insulin-like growth factor 1 receptor inhibitor to enter Phase III trials, as the class gains popularity and strength
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.